iBio Inc (IBIO) concluded trading on Thursday at a closing price of $5.05, with 4.91 million shares of worth about $24.79 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 154.79% during that period and on February 27, 2025 the price saw a gain of about 34.31%. Currently the company’s common shares owned by public are about 9.87M shares, out of which, 9.27M shares are available for trading.
Stock saw a price change of 39.12% in past 5 days and over the past one month there was a price change of 71.77%. Year-to-date (YTD), IBIO shares are showing a performance of 106.12% which increased to 324.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.05 but also hit the highest price of $4.98 during that period. The average intraday trading volume for iBio Inc shares is 246.41K. The stock is currently trading 42.09% above its 20-day simple moving average (SMA20), while that difference is up 68.43% for SMA50 and it goes to 107.06% higher than SMA200.
iBio Inc (AMEX: IBIO) currently have 9.87M outstanding shares and institutions hold larger chunk of about 26.65% of that.
The stock has a current market capitalization of $49.87M and its 3Y-monthly beta is at 1.42. It has posted earnings per share of -$2.70 in the same period. It has Quick Ratio of 1.76 while making debt-to-equity ratio of 0.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBIO, volatility over the week remained 20.34% while standing at 13.15% over the month.
Analysts are in expectations that iBio Inc (IBIO) stock would likely to be making an EPS of -0.32 in the current quarter, while forecast for next quarter EPS is -0.34 and it is -1.38 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.39 which is -0.25 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.98 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 60.55% while it is estimated to increase by 13.52% in next year. EPS is likely to shrink at an annualized rate of 45.01% for next 5-years, compared to annual growth of 57.55% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Chardan Capital Markets on May 28, 2024 offering a Buy rating for the stock and assigned a target price of $5 to it. Coverage by JMP Securities stated iBio Inc (IBIO) stock as a Mkt outperform in their note to investors on November 29, 2021, suggesting a price target of $1.50 for the stock. On January 22, 2021, Cantor Fitzgerald Initiated their recommendations, while on June 26, 2020, Alliance Global Partners Initiated their ratings for the stock with a price target of $2.55.
